The therapy, developed by PTC Therapeutics, is designed for patients across the severity of spectrum of AADC deficiency. It ...

PTC Therapeutics (PTCT) came out with a quarterly loss of $1.39 per share versus the Zacks Consensus Estimate of a loss of $1.54. This compares to loss of $1.76 per share a year ago. These figures are ...

This is the first gene therapy for AADC deficiency to receive US regulatory approval and the first that can be administered directly to the brain.

An enhanced premium tax credit for Marketplace plans will expire at 2025-end. If Congress doesn't act soon, millions may go ...

Joel Beatty has given his Buy rating due to a combination of factors related to PTC Therapeutics’ promising ... s potential to address an unmet medical need. Beatty acknowledges the strength ...

PTC Inc (PTC) reports robust financial performance with a 25% increase in free cash flow and announces a $2 billion share repurchase authorization.

Good afternoon, ladies and gentlemen, and thank you for standing by, and welcome to today's PTC 2024 fourth-quarter conference call. (Operator Instructions) I would now like to turn the call over to ...

WARREN, N.J., Oct. 1, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the FDA has accepted for filing the New Drug Application (NDA) of sepiapterin for the treatment of ...